Importantly, checkpoint inhibitor treatment both in vitro and in vivo is shown to improve hematopoiesis in MDS, supporting the notion that anti-PD-1 or anti-PD-L1 alone or in combination with other therapies will show a benefit for MDS patients. Here, CD274 is linked to myelodysplastic syndrome.